Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 4
Treating Chronic HCV Genotype 4 with a Regimen Containing an NS5A Inhibitor
Chronic hepatitis C genotype 4 is a serious and potentially life-threatening infection caused by the hepatitis C virus (HCV). Current antiviral treatments can effectively cure the infection in some cases. Many individuals with chronic HCV genotype 4 respond well to therapy with a regimen containing an NS5A inhibitor.
NS5A inhibitors are a type of direct-acting antiviral (DAA) medication. These drugs work by targeting the virus’s ability to replicate, preventing it from spreading throughout the body and causing further damage. DAA treatments such as NS5A inhibitors are generally well-tolerated and have few side effects compared to other HCV treatments.
Studies have found that individuals treated with a regimen that contains an NS5A inhibitor have higher rates of sustained virologic response (SVR) than those treated with regimens that don’t contain NS5A inhibitors. SVR is defined as the absence of detectable vial particles in the blood six months following the completion of a course of treatment.
The Benefits of Treating Chronic HCV Genotype 4 with an NS5A Inhibitor Regimen
In clinical studies, individuals with chronic HCV genotype 4 who were treated with a regimen containing an NS5A inhibitor experienced the following benefits:
- A higher chance of achieving an SVR
- Faster viral suppression
- Improved quality of life
- Fewer side effects
- Shorter treatment duration
Given these benefits, using a regimen containing an NS5A inhibitor is recommended for individuals with chronic HCV genotype 4. If you have been diagnosed with this infection, talk to your doctor about whether this type of treatment may be right for you.